Abstract
A non-sputum triage test to rule out TB disease is a WHO high-priority diagnostic and a combinatory score based on a 3-gene host-signature has shown promise in discriminating TB from other illnesses. We evaluated the accuracy of an early-prototype cartridge-assay (“Xpert MTB Host Response”, or Xpert-MTB-HR-Prototype) of this 3-gene signature on bio-banked blood-samples from PLHIV against a comprehensive microbiological reference standard (CMRS) and against Xpert® MTB/RIF on first sputum alone. We depict results based on performance targets set by WHO in comparison with a laboratory-based CRP assay. Of 201 patients included, 67 were culture-positive for Mycobacterium tuberculosis. AUC for the Xpert-MTB-HR-Prototype was 0·89 (CI 0·83-0·94) against the CMRS and 0·94 (CI 0·89-0·98) against Xpert MTB/RIF. Considering Xpert-MTB-HR-Prototype as a triage test (at nearest upper value of sensitivity to 90%), specificity was 55·8% (CI 47·2-64·1) compared to the CMRS and 85·9% (CI 79·3-90·7) compared to Xpert MTB/RIF as confirmatory tests. Considering Xpert-MTB-HR-Prototype as a stand-alone diagnostic test, at a specificity near 95%, the test achieved a sensitivity of 65·7% (CI 53·7-75·9) while CRP achieved a sensitivity of only 13·6% (CI 7·3-23·4). In this first accuracy study of a prototype blood-based host-marker assay, we show the possible value of the assay for triage and diagnosis in PLHIV.
One Sentence Summary This is an accuracy study of a blood-based host-marker assay demonstrating its potential in triage and diagnosis of active tuberculosis (TB) in people living with HIV (PLHIV).
Competing Interest Statement
ES, DHP, SB, LSM, JP and DG are employed by Cepheid.
Funding Statement
This work was funded by the UK Department for International Development (DFID) grant number 300341-102, Dutch Ministry of Foreign Affairs grant number PDP15CH14, Australian Department of Foreign Affairs and Trade (DFAT) grant number 70957 and the German Federal Ministry of Education and Research (BMBF) through KfW (grant number 2020 62 156). PK is funded in part by Bill & Melinda Gates Foundation (OPP1113682), NIH/NIAID (5U19AI109662-05, 5R01AI125197-02, 5U19AI057229), Department of Defense (W81XWH-18-1-0253, W81XWH1910235), and Ralph & Marian Falk Medical Research Trust. Cepheid performed the testing and provided the cartridges at their own cost. ES, DHP, SB, LSM, JP and DG are employed by Cepheid.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All study-related activities were approved by the Human Research Ethics Committee (HREC) of the University of Cape Town (UCT) and the Universidad Peruana Cayetano Heredia (UPCH).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
# Disclaimer: Product in development. Not for use in diagnostic procedures. Not reviewed by any regulatory body.
Data Availability
None